The RK-1 continuous mixing processor from Readco Kurimoto is suited for testing formulations in continuous processing conditions.
Courtesy Readco
Process equipment manufacturer Readco Kurimoto introduced the RK-1 continuous mixing processor, which incorporates the company's proprietary mixing technology in a compact, tabletop unit. The company states that the unit was developed to help product development professionals test new and existing formulations being processed in batches using a continuous process in a controlled, laboratory environment. Scaled down to process 10 lbs/hr, the RK-1 combines heat transfer, mixing, and shear to process multiple powdered, liquid, and viscous ingredients in a single step, while yielding a high quality, homogeneous product at discharge that meets targeted specifications for moisture, texture, color, uniformity, and other criteria.
The novel RK-1 features twin shaft, co-rotating screws with a one-inch diameter set within a closed barrel to promote the intimate contact among wet and dry materials needed to achieve the desired level of mixing, blending, reacting, crystallization, and/or encapsulation. Suitable for use in research and development laboratories for pharmaceuticals and other products, the versatile RK-1 includes touch-screen controls for setup, monitoring, and real-time adjustments. Other available options include a mobile lift table, electric band heater, feed chute, and all-stainless steel construction.
The RK-1 continuous processors are engineered and manufactured in the company's York, PA headquarters. The lab-size processors operate on 220 volts single-phase and are delivered ready to plug in and operate.
Source: Readco
Clinical Supply Planning in Europe - Balancing Cost, Flexibility and Time
December 19th 2024The packaging and distribution of clinical supplies is a fundamental piece to the overall success of a clinical trial, and advance preparation can help establish a more efficient supply chain. Selecting the best geographical location for those activities, however, depends on the clinical trial protocol, business decisions, and even the investigational medicinal product (IMP) being studied.